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Abstract 
 
Objectives: High frequency repetitive transcranial magnetic stimulation (HF-rTMS) has proven 
antidepressant effects, but the optimal frequency of sessions remains unclear.  
Methods: We conducted a 3-week, sham- controlled trial to assess the antidepressant efficacy of 
one session/day (A1 Group) compared to two active HF-rTMS sessions/ day (A2 group) and 
equivalent sham sessions (once/day--S1 Group, twice/ day--S2 Group) in patients with treatment-
resistant major depression (TRD), with a subsequent 2-week follow-up period. 177 patients were 
screened, of whom 105 met eligibility criteria and 98 consented and were randomized. HF- 
rTMS(20 Hz) was targeted to the left prefrontal cortex in sessions of approximately 40 trains (2 
sec each) at 100 % resting motor threshold, with an inter-train interval of 1 min. Treatment 
response was defined as a ≥50% decrease in Hamilton Depression Rating Scale (HDRS) score 
and/ or Clinician Global Impressions-Severity of Illness (CGI-S) score ≤3. Remission was defined 
as HDRS score ˂8 and/ or CGI-S score ≤2.  
Results: Practically none of the subjects in either sham groups achieved remission. Increased odds 
of remission were present for CGI-S by stimulating twice rather than once per day (OR=1.5, 
p=0.018) while there was a marginal result for HDRS (OR=3.9, p=0.066). Patients who had lower 
baseline HDRS (OR=0.75, p=0.014) and CGI-S scores (OR=0.18, p=0.001) were more likely to 
achieve remission.  
Conclusions: Twice per day active HF- rTMS might be more effective than once per day active 
HF-rTMS or sham stimulation. 
 
 
Key words: Depression, randomized controlled trial, Transcranial Magnetic Stimulation (TMS). 
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Introduction 
A large number of patients with Major Depressive Disorder (MDD) do not respond to two or more 
antidepressant medication treatments1-3. Repetitive transcranial magnetic stimulation (rTMS) is a 
non-invasive method to stimulate the brain4-6. Several studies, involving patients with MDD, were 
conducted with the use of high frequency rTMS (HF-rTMS) 7-9.  
HF-rTMS has antidepressant effects in sham-controlled trials10, 11 and naturalistic studies12-15, with 
efficacy supported in several recent systematic reviews and meta-analyses 16-21.  However, there 
are concerns regarding the quality of some studies 5 and the definition of optimum treatment 
indications and regimen22, 23. 
One important unresolved issue is the number of times per day that HF-rTMS should be delivered 
24. Loo et al.25, in a 2-week randomized controlled trial (RCT), found that twice a day HF-rTMS 
is safe and better than placebo, but did not compare twice a day rTMS with once a day. We are not 
aware of any study directly comparing twice a day vs. once a day rTMS for treatment of treatment-
resistant major depression (TRD). We present here results of a RCT to assess the antidepressant 
efficacy of two HF-rTMS sessions /day vs. one session/ day vs. sham stimulation once or twice/ 
day in patients with TRD. 
 
 
Materials and Methods  
Sample  Recruitment 
The study was approved by the Eginition University Hospital Research Ethics committee and was 
consistent with the Declaration of Helsinki. The trial protocol with reference no 0527821514 can 
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be accessed at http://www.eginitio.gr/Erevna/.  The study is registered (http://controlled-
trials.com/ ISRCTN71929667). Patients were recruited from the outpatient service of Eginition 
Hospital, Athens, Greece between July 2006 and December 2011. Eligible subjects had to be 18-
59 years old, right-handed, meet DSM-IV-TR criteria26  for current non-psychotic MDD, be naïve 
to TMS, and without history of seizures, head injury with loss of consciousness, brain surgery, 
presence of metallic implants, dementia or other Axis I diagnosis, substance dependence or abuse 
within the previous 6 months, or pregnancy; Diagnoses were confirmed using the Mini-
International Neuropsychiatric Interview (MINI)27 and the Structured Clinical Interview for DSM-
IV Axis I Disorders (SCID)28.  
Patients had to be at least stage 2 treatment resistant (failure of at least two adequate trials of two 
different major classes of antidepressant) according to criteria by Thase and Rush29. Patients 
referred for treatment were screened for eligibility.  Of the 177 patients screened, 105 were found 
eligible. All subjects were provided with full written information about the nature and purpose of 
the study and 98 gave written informed consent to participate (Table 1). 
If clinically appropriate, subjects were encouraged to discontinue medication prior to study entry. 
If this was not possible, subjects were kept on a minimum antidepressant regimen, in order not 
to risk a recurrence of severe depressive symptoms (venlafaxine 75-112.5 mg/day, mirtazapine 
30-45 mg/day, citalopram 20-30 mg/day); if taking benzodiazepines, a dose no greater than the 
equivalent of 1 mg clonazepam/ day was permitted. The medication regimen was kept stable for 
at least 4 weeks before study entry and throughout the study period.  
Design 
The study was a parallel-group, randomized, sham-controlled trial with 4 treatment groups: the 
once daily active stimulation group (A1), the twice daily active stimulation group (A2), the once 
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daily sham stimulation group (S1) and the twice daily sham stimulation group (S2) (Table 1). To 
ensure allocation concealment, following baseline assessment by trained physician-raters, patients 
were randomly assigned to receive a course of active or sham rTMS once or twice/ day by an 
independent researcher using a password-protected computer database containing the 
randomization list. “Treaters” were residents in psychiatry who were blind to the study protocol 
and naïve to rTMS; they were told this was a study comparing two methods of active rTMS. 
“Treaters” were not allowed to deliver rTMS outside the study and were advised not to discuss the 
study protocol with patients and raters.   
Patients had 15 (once a day) or 30 (twice a day) treatment sessions on consecutive weekdays 
(starting Monday) for 3 weeks. All the patients would come in the morning around 8.00 am for 
the first treatment session (both once and twice a day) and in the afternoon around 5.00 pm if 
they were scheduled for a second treatment session (only twice a day). Patients and raters were 
blind to allocated treatment; only physicians responsible for the study protocol (CT, CP, PS) 
knew the treatment being delivered. To check blinding, patients were asked to guess which 
treatment had been received (“active TMS,” “sham TMS,” “can’t guess”) at the beginning of 
visit 2 and after visit 15 and raters after visit 15.  The period of clinical assessment was extended 
two more weeks beyond the completion of rTMS sessions because we have an indication that 
rTMS sometimes produce a late effect for some of the patients. 
 
TMS Procedure 
HF-rTMS sessions took place in the TMS Unit, Eginition Hospital, Athens, Greece. At screening, 
experienced TMS researchers identified and marked on a swim cap (separate for each subject) the 
vertex, the scalp location for optimal stimulation of the motor cortex (MC) controlling the right 
7 
 
first dorsal interosseous (FDI) muscle, and the point 5 cm anterior to the motor cortex location 
along a left superior oblique plane (treatment stimulation site-left prefrontal cortex). Subsequently, 
subjects had structural MRI while wearing the swin cap with attached fiducials (vitamin E 
capsules) placed over the MC and the left prefrontal cortex (PFC) 30. If the fiducial intended to be 
over PFC was actually over the premotor cortex, it was moved 1 cm anterior (this occurred in 
34.7% of patients). At the beginning of each treatment session, motor threshold (MT) was 
determined by delivering single TMS pulses to the motor cortex for the right FDI muscle, with 
continuous EMG monitoring. MT was defined as the percent output of the stimulator that induced 
at least a 50-μV motor evoked potential in 5 of 10 single stimulations. After baseline, MT was 
determined once more at the beginning of the 8th rTMS session.  
 “Treaters” used a Magstim ultra rapid stimulator (Magstim Company Limited, Whitland, UK), 
with a figure-eight magnetic coil applied over PFC. Each session of HF rTMS treatment consisted 
of approximately 40 trains of 20 Hz at 100 % MT, with train duration 2 s and inter-train interval 
of 1 min, yielding 1600 pulses/session. These stimulation parameters are in accordance with 
international TMS safety guidelines 31, 32. Total pulses were 24,000 for the once per day rTMS 
group and 48,000 pulses for the twice per day rTMS group. For active TMS, the coil was placed 
flat against the scalp with the handle and short axis of the coil oriented in a parasagittal plane and 
the intersection of the figure-eight windings centered over PFC. Sham TMS was delivered in the 
same anatomical location with identical stimulation parameters but with the lateral edge of the coil 
rotated 90° away from the scalp. The sham subjects went through the same procedures as the active 
TMS subjects up to the point of the coil rotation. 
 
Outcome Measures 
8 
 
Outcome measures were the 17-item Hamilton Depression Rating Scale score (HDRS- Hamilton, 
1960) 33 and the Clinician Global Impressions-Severity of Illness score (CGI-S)34. Patients were 
evaluated at baseline (before randomization) and at the end of the 1st, 2nd, 3rd and 5th week. 
Additional baseline data obtained by patient interview and case note review included age, sex, past 
history of depression and ECT, number of medication treatment steps for the current depressive 
episode (according to the criteria of Thase and Rush29), and current antidepressant and/or 
benzodiazepine medication.  
For HDRS, response was defined as a decrease of ≥50% from baseline and remission as HDRS 
score˂ 8. For the CGI-S, response was defined as an endpoint rating of 3 or less (corresponding to 
“mildly ill” or better), whereas remission as an endpoint rating of 2 “borderline mentally ill” (2) 
or 1 “normal/not at all ill”34.The inter- rater reliability (intra-class correlation coefficient) for the 
outcome measures were 0.95 for HDRS and 0.97 for the CGI-S. 
 
Statistical analysis  
Continuous variables are presented as mean and standard deviation (SD), while qualitative 
variables are presented as absolute and relative frequencies. Bonferroni post hoc correction for 
multiple comparisons was used to assess differences in baseline characteristics between groups. 
Mixed effects regression was used in order to study the differences in the outcome variables over 
the 3-week treatment period and the follow-up period and evaluate differences among the four 
study groups. For each outcome measure, a mixed effects model was employed in order to evaluate 
the treatment effect during the five weeks course, allowing for different intercept and slope for 
each individual (the random intercept and slope model constituted an improvement over the 
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simpler random intercept model, as indicated by the corresponding likelihood ratio tests for nested 
models: HDRS χ2 (2)=32.5, p<0.001; CGI χ2(2)=29.3, p<0.0001).  
The reference category for the group was set as the A1 group and the follow up (week 5) in order 
to facilitate the interpretation of the coefficients in Table 4. The analysis was repeated considering 
the 5-point time variable as numerical. This approach allows us to consider a quadratic effect for 
time.  One-way analysis of variance (ANOVA) was used to evaluate group differences at the 
follow-up.  
Multiple logistic regression analyses using a stepwise method including various independent 
variables (i.e., gender, age, stage of treatment resistance according to the Thase and Rush criteria, 
current antidepressant and benzodiazepine use, HDRS baseline score) were performed to identify 
predictors of treatment outcome (response or remission), based on HDRS and CGI-S scores. All 
reported p values are two-tailed and statistical significance was set at 0.05. Analyses were 
conducted using STATA 13. 
 
Power Analysis  
Power analysis methodology for this study represents a design with four levels of the between-
subject factor (four treatment groups) and five levels of the within-subjects factor (time in weeks). 
Sample size was determined using previously published effect size estimates (Avery et al.35- 
differences in rates of response between the sham and TMS groups with a 0.69 effect size) and 
indicated 90% power for a two-tailed test of significance at p<0.05. 
 
Results  
Sample characteristics per study group 
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177 patients were screened, of whom 105 met eligibility criteria and 98 consented and were 
randomized (Table 1). The four study groups were similar in terms of age, sex, medication, Rush 
and Thase stage, and HDRS and CGI- scores at baseline (Table 2). Of the 98 randomized patients, 
27 patients received once daily sessions of active HF-rTMS (A1 group), 27 patients received twice 
daily sessions of active HF-rTMS (A2 group), 20 patients received sham stimulation once per day 
(S1 group) and 24 twice per day sham stimulation (S2 group). Eighty-nine subjects completed the 
5-week trial and nine (9%) discontinued (2 from A1 group; 2 from A2 group; 2 from S1 group; 3 
from S2 group) (Table 1): one for protocol violation (a treater discussed study protocol with a 
patient), two due to exacerbation of pre-existing headache, 5 were unable to attend treatment 
sessions due to financial and work-related reasons, and one hospitalized with influenza. The basic 
analysis was conducted on the intent-to-treat sample, i.e., the 96 individuals who had 
measurements at week 1 (Table 1). The sample was reduced to 89 for models that refer to the 
differences between baseline and follow-up (for details see the Results section). 
 
Treatment Efficacy   
Time course analysis of change of Mean scores for HDRS and CGI-S   
There were no significant differences among treatment groups on any baseline measure (Table 2).  
Table 3 and Figure 1 present the changes in outcome measures over time, for each group 
separately. The mean scores were significantly different between the A1 group and the other three 
groups (Week 5- “follow up”) for both outcome measures. In particular, the A2 group had 
significantly lower mean scores than the A1 group, while both sham groups had significantly 
higher scores. No significant interactions emerged for the A2 group and time, while for the sham 
groups the interactions were significant, with the exception of the fourth week for CGI-S. In 
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relation to the score differences between the primary endpoint (3 weeks) and the end of the study 
(5 weeks), no statistically significant differences were present in the HDRS  in the S1 (p=0.75) 
and S2  (p=0.118)  whilst the differences were significant in the A1 (p=0.001) and A2 (p<0.001) 
groups. In the case of CGI, the only significant difference was present in the A2 group (p=0.046, 
whilst p>0.1 in all other groups). 
--- Table 4 --- 
The analysis considering time as a numerical variable yielded similar results. Significant effects 
emerged for the linear (HDRS: bt=1.2, p<0.001 / CGI-R: bt=0.3, p<0.001) and the quadratic time 
(HDRS: bt2=0.5, p<0.001 / CGI-R: bt2=0.06, p<0.001). The A1 group had significantly higher 
mean than the group A2 (HDRS: bA2=-3.6, p=0.026 / CGI-R: bA2=-0.7, p=0.011) and lower means 
than the sham groups (HDRS: bS1=15.3, p=0.026 – bS2=17.2, p<0.001 / CGI-R: bS1=2.3, p<0.001 
– bS2=2.6, p<0.001). No significant interactions with time emerged for the A2 group, but the 
interactions were again significant for the sham groups (p<0.001 in all cases). 
 
 
Response and Remission  
Only one individual (2.5%) in the sham groups had a treatment response based on HDRS score, 
as opposed to 29 (59.2%) for the active groups (χ2=31.666, df=1, p<0.001). Similarly, only 5 
individuals (12.5%) has a response based on CGI-S scores in the sham groups, as opposed to 49 
(100%) in the active groups (χ2=70.664, df=1, p<0.001). The logistic regression found that 
likelihood of a treatment response (in terms of HDRS) in the active rTMS groups was significantly 
associated only with frequency of rTMS sessions (OR=5.2, p=0.027), baseline HDRS score (OR= 
0.7, p=0.010), and current medication status (OR=5.2, p=0.033) (with each OR controlled for the 
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other two). Logistic regression could not be done for CGI-S scores, as all individuals had CGI-S 
score ≤3.   
No one in the sham groups was in remission (based on HDRS) at follow-up, as opposed to 12 
(24.5%) of the individuals who received active treatment (χ2=11.323, df=1, p=0.001). Similar 
results occurred for remission based on CGI-S (2.5% versus 51% for the sham and active groups, 
respectively, χ2=25.072, df=1, p<0.001). The logistic regression found that likelihood of remission 
in the active groups was significantly associated with baseline scores (HDRS OR=0.75, p=0.014; 
CGI-S OR=0.18, p=0.001) and with number of rTMS sessions per day (CGI-S OR=1.5, p=0.018; 
HDRS OR=3.9, p=0.066). 
 
Integrity of the Blind  
The four treatment groups did not differ significantly in their guesses about which treatment they 
received after the first (p=0.8) and last rTMS session (p=0.6). Likewise, raters did not guess better 
than chance which subjects received active treatment (p=0.7).  However, the response to rTMS 
treatment did appear to influence subjects’ thoughts about what they received.  After the 15th day 
of rTMS, 100% of the 12 patients (3 from the A1 group and 9 from the A2 group) who achieved 
remission thought they were receiving active TMS vs. 46.8% of non-remitters (36/77) (p=0.001). 
Similarly, after the 15th day of rTMS, 82.7% of the patients (24/29) with a treatment response 
thought they were receiving active TMS vs. 40% (24/60) of non-responders (p<0.001). 
 
Adverse Effects 
rTMS sessions were generally well tolerated. No seizures occurred. Seven patients from the A1 
group, six from the A2 group, five from the S1 group, and six from the S2 group complained of 
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discomfort at the site of stimulation. Nine subjects (3 from A1 group, 2 from A2 group, 1 from S1 
group and 3 from S2 group) experienced exacerbation of pre-existing headache; one subject from 
A1 group and one from S2 group discontinued the trial because of this. One patient was 
hospitalized with influenza (not considered study related). There were no significant group 
differences in proportion of subjects with various adverse effects. 
 
Discussion 
Findings 
To our knowledge, this is the first randomized sham-controlled trial to compare the effectiveness 
of twice daily vs. once daily HF- rTMS sessions for treatment of TRD. It is proposed that twice 
daily sessions might be more effective in terms of both response and remission rates. There was a 
slight discrepancy, however, between the CGI-S results and HDRS results (increased odds of 
remission were present for CGI-S by stimulating twice rather than once per day while there was a 
marginal result for HDRS); yet, other studies have also come across similarly discrepant results 
when different outcome measures were used25. It is of note, that Bandelow et al.34 suggest that a 
CGI-S score of 2 or less indicates remission while a CGI-S score of 1 indicates complete or 
symptom free remission (this might explain the discrepancy observed between the CGI-S 
remission scores and HDRS-remission scores).   
 
Relation to previous studies 
Number of stimulations per session and per day, duration of treatment per weeks 
In our study, a 3-week treatment period was used, each session consisted of 1600 pulses (24000 
pulses for the A1 group and 48000 for the A2 group for the whole course). Avery et al. 35 in a 3-
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week controlled study comparing active and sham stimulation (1600 pulses/day and 24000 
pulses for the whole course similar to the A1 group in this study) found response rate to be 31% 
(compared to 37% for the A1 group in this study) and remission rate 20% (compared to 11% for 
the A1 group in this study) based on HDRS scores. Nevertheless, results may be different from 
other RCT studies10; various factors could have contributed to this: age of patients, chronicity of 
the condition, medication, localization of the stimulation point, the frequency of tms stimulation 
might have also been a factor. We have rarely noticed so good results with frequency of 10 Hz 
compared to 20 Hz 36.  
In the study by O’Reardon et al., 10 stimulation period was extended to 4-6 weeks, Indeed larger 
stimulation periods might investigate better the efficacy of rTMS; however, withdrawal rate 
could be high 37.  We have chosen a 3-week stimulation period to retain in the study the larger 
number of patients possible; this was actually the minimum treatment period suggested in the 
study by George et al. 11   
Having more rTMS sessions during each day38-41 and increased number of pulses per day 42-45, as 
in our study, might retain more patients37 and have faster antidepressant effects. Within this 
context, Holtzheimer et al. 42 employed 15,000 rTMS pulses for over 2 days, while Hadley et al. 43 
employed 6800 pulses per session and 5 sessions per week (34,000 pulses per week) for 2 weeks 
(10 sessions). MacDonald et al. 44 found that patients who remitted during fast left-sided treatment 
received a mean of 26 active treatments (90,000 pulses). Finally, George et al. 45 delivered 54,000 
pulses of left prefrontal rTMS over three days to suicidal inpatients and found high doses of rTMS 
to be feasible and safe over a short treatment period. We think that the number of pulses per day 
is a very significant factor for remission; however many patients, especially the ones experiencing 
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adverse effects may need more sessions per day, because they cannot tolerate increased number of 
pulses per session. 
 Adverse effects 
 The treatment was relatively well tolerated, with no significant difference in adverse effects 
between rTMS and sham groups or between once daily and twice daily sessions and high retention 
rate (90.8%) HF-rTMS has previously been found safe even in patients with serious physical 
conditions 46. 
 
Factors influencing response and remission  
Both twice daily rTMS sessions and concurrent antidepressant medication were associated with 
better treatment response. Recently, it has been proposed 11, 47 that greater rates of response and 
remission would be seen if TMS were delivered in combination with pharmacotherapy. Several 
studies48-50 and meta-analyses51, 52 suggest that HF-rTMS may accelerate response to 
antidepressants and provide clinical improvement comparable to triidothyronine and pindolol 
augmentation. In the present study, we found that patients on antidepressants exhibited greater 
response but not greater remission rates, possibly due to short follow-up period.    
In previous studies, younger age12, 53, 54, less treatment resistance53, 55, 56, lower baseline symptom 
severity12, 54, and lack of comorbid anxiety disorders 56 were associated with better response. In 
our study, no effect was found regarding age, possibly because all our patients were relatively 
young; we did find the expected association with lower baseline symptom severity, but not with 
TRD stage29. We did not examine the presence of comorbid anxiety disorders. Carpenter et al.12 
found that TRD level was a modest predictor of benefit from TMS treatment, while, Shutter 8 also 
reported that treatment resistance does not play a major role in TMS antidepressant effect. Finally, 
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Demitrack and Thase57 found rTMS efficacy to be similar to that of antidepressant therapy or 
atypical antipsychotic augmentation in TRD.  
Blinding and placebo effects  
“Treaters” were not blind to treatment allocation, potentially jeopardizing the blinding of 
subjects. Furthermore, we did not have a sham coil that could deliver somatosensory sensations 
matched to active stimulation11. Sham TMS consisted of active pulses delivered to the same 
anatomical location with identical stimulation parameters but with the lateral edge of the coil 
rotated 90° away from the scalp. This sham rTMS approach produced acceptable levels of 
blinding in previous studies 58. Furthermore, debriefing data from both the patients and raters 
indicated that the blind was successfully maintained. George et al.11 reported that 48% of clinical 
raters guessed correctly (35% correct for active rTMS and 59% for sham) while 84% of their 
guesses were not confident. Lisanby et al.59 found that tilting the coil at a 90° angle, like in the 
present study, produced minor therapeutic effects (only 29% of the peak integrated voltage of the 
actual TMS stimulation). In our study, sham rTMS appeared to have no therapeutic effect, as 
only one subject in the sham groups had any treatment response. In other studies a larger 
response and remission rate were observed for the sham stimulation group 11, 35. George et al. 11 
reported that those patients who remitted either in the sham or the active group seemed to be less 
resistant to treatment. It is possible that our patients were more resistant to treatment than the 
ones in other studies11, 35. For example, in the study by Avery et al.35 very similar to ours (for 
what concerns stimulation parameters and sham condition), the TMS group and sham group 
differed by 25% ((11/35) 31% -6% (2/33)) in response rate and by 17% ((7/35) 20% - 3% (1/33)) 
in remission rate.  In our study, A1 group and S1 group differed in response rate by 32% ((10/27) 
37% - 5% (1/20)) while remission in the two groups differed by 11% ((3/27) 11%  - 0% (0/20)). 
17 
 
It is worth noting that there was a greater remission rate in the study by Avery et al. 35 both for 
the active and sham group. In our study only 3/27 subjects (11%) from A1 group remitted 
compared to 7/35 (20%) in the active group and 1/33 (3%) in the sham group in the study by 
Avery et al.35. 
 
 
Localization of PFC 
Precise PFC location could increase TMS efficacy11, 60. We used structural MRI to locate PFC; in 
34.7% of patients PFC was found in a more anterior position than the one dictated by the 5 cm 
rule.  
 
Study Limitations 
A number of study limitations should be taken into account. First, raters and “treaters”, though 
blind to the study protocol, were from the same academic center. Second, we were not able to 
evaluate cognitive function; however, several studies have indicated that rTMS is relatively safe 
in this domain25, 61. Third, the follow-up period was short because we did not want TRD patients 
to remain untreated for longer periods. This study cannot comment on the duration of effects 
beyond two weeks.  
 
Conclusions 
Twice per day active HF- rTMS might be more effective than once per day active HF-rTMS in 
patients with TRD. Larger multi-centered studies should verify the above-mentioned results. 
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 Table 1: Flow Chart 
 
Excluded n=79  
Not meeting criteria for inclusion n=72 
Declined to participate n=7 
 
98 patients consented and were randomized 
27 patients received once 
per day active rTMS 
(A1 Group) 
 
27 patients received twice 
per day active rTMS  
(A2 Group) 
 
 
20 patients received once 
per day sham stimulation 
(S1 Group) 
 
24 patients received twice 
per day sham stimulation 
(S2 Group) 
 
2 discontinued  
(1 due to work-related 
reasons and 1 due to 
exacerbation of pre-
existing headache)  
 
 
25 completed TMS 
sessions 
2 discontinued due to 
work-related and financial 
reasons 
 
 
 
 
25 completed TMS 
sessions 
 
2 discontinued   
(1 protocol violation,        
1 discontinued due to 
financial reasons) 
  
 
 
18 completed    TMS 
sessions          
 
 
177 patients screened 
3 discontinued  
(1 due to influenza, 1 due 
to work-related reasons, 
and 1 due to exacerbation 
of pre-existing headache) 
 
 
21 completed TMS 
sessions          
25 completed follow up 25 completed follow up 
 
18 completed follow up    21 completed follow up 
 
      26 were analyzed      26 were analyzed     20 were analyzed 
 
     24 were analyzed 
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Table 2: Baseline characteristics (per group) of adults with treatment-resistant major depression receiving HF rTMS treatment 
(N=96). 
 Treatment Group Difference  
between groups A1  A2  S1  S2  
Age (years): Mean (sd) 39.1 (10.1) 38.9 (13.9) 38.0 (9.9) 39.4 (8.9) F(3,92)=0.070, p=0.976* 
Gender: N (%) of males 11 (44.0) 15 (57.7) 10 (47.6) 14 (58.3) χ2=1.526, df=3, p=0.676 
Medication: N (%) of receiving 14 (56.0) 16 (61.5) 9 (42.9) 15 (62.5) χ2=2.008, df=3, p=0.530 
Rush and Thase stage: N (%) of ≥4 7 (28%) 6 (23%) 4 (18%) 7 (29%) χ2=0.660, df=3, p=0.883 
HDRS at baseline: Mean (sd) 30.6 (3.2) 29.7 (4.6) 29.4 (3.2) 30.3 (3.6) F(3,92)=0.529, p=0.663* 
CGI-S at baseline: Mean (sd) 4.8 (0.6) 4.5 (0.6) 4.8 (0.7) 5.0 (0.7) F(3,92)=2.677, p=0.052* 
* Bonferroni post hoc correction indicated no differences between groups.  
Abbreviations:  A1: Active rTMS-- 1 session/day, A2: Active rTMS-- 2 sessions/day, S1: Sham rTMS--1 
session/day, S2: Sham rTMS--2 sessions/day. 
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Table 3: Mean (standard deviation) for the two outcome measures at each time point, per group. 
 
Group 
A1 A2 S1 S2 
H
D
R
S
 
baseline 30.6 (3.2) 29.7 (4.6) 29.4 (3.2) 30.3 (3.6) 
Week 1 26.2 (3.8) 24.9 (4.2) 28.2 (4.7) 28.7 (4.1) 
Week 2 20.1 (3.6) 18.2 (4.6) 26.6 (4.7) 27.7 (4.0) 
Week 3 15.6 (3.7) 13.1 (4.5) 25.4 (5.3) 27.0 (4.0) 
follow up 14.9 (4.1) 12.3 (5.1) 25.9 (5.8) 27.4 (4.1) 
 
 
 
 
 C
G
I 
baseline 4.8 (0.6) 4.5 (0.6) 4.8 (0.7) 5.0 (0.7)
Week 1 4.2 (0.6) 3.9 (0.5) 4.5 (0.8) 4.5 (0.7) 
Week 2 3.5 (0.5) 3.0 (0.7) 4.4 (0.8) 4.5 (0.7)
Week 3 2.6 (0.7) 2.1 (0.9) 4.2 (0.8) 4.4 (0.7) 
follow up 2.5 (0.7) 1.9 (0.8) 4.3 (0.9) 4.5 (0.7) 
A1: Active & 1 session/day, A2: Active & 2 sessions/day, S1: Sham & 1 session/day, 
S2: Sham & 2 sessions/day. 
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Table 4:  Effect of HF rTMS given one or two sessions daily on symptoms of major depression:  Mixed effects regression (random 
intercept and random slope) coefficients, referring to week s 1 to 3, adjusted for the baseline measures. 
 
  HDRS CGI-S 
b s.e. z p-value b s.e. z p-value 
        baseline 0.9 0.1 13.0 <0.001 0.6 0.1 8.2 <0.001 
group1:   
          A2 -1.8 1.0 -1.8 0.077 -0.3 0.2 -1.6 0.112 
          S1  11.0 1.1 10.3 <0.001 1.6 0.2 7.7 <0.001 
          S2  12.0 1.0 11.5 <0.001 1.7 0.2 8.4 <0.001 
week2:   
          1  10.2 0.5 22.2 <0.001 1.6 0.1 12.0 <0.001 
          2  4.5 0.4 12.3 <0.001 0.9 0.1 9.0 <0.001 
group x week   
        A2-1  1.4 0.6 2.1 0.036 0.2 0.2 1.1 0.257 
        A2-2 0.5 0.5 1.0 0.333 0.0 0.1 0.3 0.760 
S1-1  -7.9 0.7 -11.4 <0.001 -1.3 0.2 -6.2 <0.001 
S1-2 -3.3 0.6 -6.0 <0.001 -0.7 0.2 -4.6 <0.001 
S2-1 -9.2 0.7 -13.6 <0.001 -1.5 0.2 -7.7 <0.001 
S2-2 -3.9 0.5 -7.3 <0.001 -0.8 0.1 -5.5 <0.001 
constant -11.4 2.2 -5.1 <0.001 -0.4 0.4 -1.0 0.320 
1reference category: A1. 2reference category: week 3.  
A1: Active & 1 session/day, A2: Active & 2 sessions/day,  
S1: Sham & 1 session/day, S2: Sham & 2 sessions/day. 
   
 
 
 
 
